KoBioLabs
KoBioLabs is recognized for its international level of technical skills by publishing a number of domestic and foreign patent papers in the fields of microbiome analysis, probiotics, and microbiome treatment technologies of various samples. In particular, our researchers are recognized both domestically and internationally, as well as internationally, as they represent Korea at the ongoing Interaional Human Microome Consortium [IHMC].
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Medical Monitoring
- Market Focus:
- Internationally (various countries)
About us
Microbiome
Microbiome is a compound word of Microbiota and Genome, which are 'microbiota and symbiotic microorganisms in the human body.'
Second Genome
The human microbiome is more than twice as many cells as the pure body, and more than 100 times more genes, so it's called the second genomic.
Technology Trends
Microbiome is widely used in the development of new drugs and the study of treatments for incurable diseases, and is also used in various fields such as food and cosmetics.
Reliable & High Quality Laboratory
- A happy company for employees
- Develop products for a healthy and happy life for customers
- Best efforts for high return on investment for investors
History
KBLP-007 phase 2a study approval (US)
KBLP-007 phase 2a study IND filing (US)
KBLP-002 phase 1 study completion
Licensing agreement with Kolmar Korea Holdings
KOSDAQ stock market enlisted (IPO)
US FDA IND Approval of KBLP-001 phase 2 study
KBLP-001 phase 1 study completion
KBLP-007 Non-IND human PoC study for ulcerative colitis initiated (KR)
KBLP-002 Non-IND human PoC study for asthma initiated (KR)
KBLP-002 Phase 1 HREC approval (AU)
KBLP-001 phase 1 study HREC approval (AU)
27b Pre-IPO funding completed
Attracted ?4b strategic investment from CJ CheilJedang Co., Ltd.
KBLF-001/KBLF-002 IRB approval of human study in Samsung Medical Center (KR)
(Non-IND human PoC study for atopic dermatitis)
KBLF-003 IRB approval of human study in Samsung Medical Center (KR)
(Non-IND human PoC study for depression)
Established KoBioLabs Australia Pty Ltd.
Received the Ministry of Science and ICT Award
Psychiatric program, selected as government sponsored project by MOTIE(Ministry of Trade, Industry and Energy)
10b Series A funding closed
Atopic dermatitis program, selected as government sponsored project by MOTIE(Ministry of Trade, Industry and Energy)
Chronic kidney disease program, selected as government sponsored project by MSS(Ministry of SMEs and Startups)
C. diffinfection program, selected as government sponsored project by MSIP(Ministry of Science, ICT and Future Planning)
1.5b Pre-Series A funding closed
Corp R&D institute established
Certification of Venture Business
Kobiolabs, Inc. founded, a spin-off from Microbiome Center at Seoul National University